moxonidine has been researched along with Left Ventricular Dysfunction in 3 studies
moxonidine: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 268 patients with chronic heart failure in NYHA functional class II to IV on optimal standard therapy were randomized to placebo or 1 of 5 doses of moxonidine SR: 0." | 9.10 | Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Dargie, H; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2002) |
| "Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure." | 7.79 | Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. ( Hirooka, Y; Honda, N; Ito, K; Kishi, T; Matsukawa, R; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K, 2013) |
| "A total of 268 patients with chronic heart failure in NYHA functional class II to IV on optimal standard therapy were randomized to placebo or 1 of 5 doses of moxonidine SR: 0." | 5.10 | Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Dargie, H; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2002) |
| "Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure." | 3.79 | Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. ( Hirooka, Y; Honda, N; Ito, K; Kishi, T; Matsukawa, R; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K, 2013) |
| " This study evaluates the effects of moxonidine and metoprolol on cardiac hemodynamics and survival in ADR-induced left ventricular dysfunction (total dose of 20 mg/kg in a 4-week regimen)." | 3.72 | Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats. ( Bellmont, S; Christen, MO; La Roche, B; Monassier, L; Thomas, L, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, N | 1 |
| Hirooka, Y | 1 |
| Ito, K | 1 |
| Matsukawa, R | 1 |
| Shinohara, K | 1 |
| Kishi, T | 1 |
| Yasukawa, K | 1 |
| Utsumi, H | 1 |
| Sunagawa, K | 1 |
| Thomas, L | 1 |
| Bellmont, S | 1 |
| Christen, MO | 1 |
| La Roche, B | 1 |
| Monassier, L | 1 |
| Swedberg, K | 1 |
| Bristow, MR | 1 |
| Cohn, JN | 1 |
| Dargie, H | 1 |
| Straub, M | 1 |
| Wiltse, C | 1 |
| Wright, TJ | 1 |
1 trial available for moxonidine and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
Topics: Blood Pressure; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doub | 2002 |
2 other studies available for moxonidine and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure.
Topics: Animals; Antihypertensive Agents; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Imidaz | 2013 |
Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats.
Topics: Adrenergic beta-Antagonists; Animals; Antibiotics, Antineoplastic; Dose-Response Relationship, Drug; | 2004 |